0.21% -0.0017

Scynexis Inc (SCYX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SCYX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Scynexis Inc Stock (SCYX) Company Profile

Scynexis Inc

Healthcare (1174)

201-884-5485

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SCYX's Discussions on Twitter

Vergleichen Sie SCYX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SCYX Scynexis Inc	0.8203	34.56M	135.87M	72.20M	45.09M	1.42
ZTS Zoetis Inc	164.86	75.07B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.88	50.02B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.21	46.82B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.20	19.78B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	283.03	14.42B	2.99B	1.21B	1.13B	25.06

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-01-22	Eingeleitet	Guggenheim	Buy
2021-01-06	Eingeleitet	Cantor Fitzgerald	Overweight
2018-07-11	Hochstufung	Needham	Hold → Buy
2018-06-27	Eingeleitet	Maxim Group	Buy
2017-10-24	Eingeleitet	Guggenheim	Buy
2017-07-10	Eingeleitet	ROTH Capital	Buy
2017-05-09	Herabstufung	Needham	Buy → Hold
2017-03-03	Bestätigt	RBC Capital Mkts	Outperform
2016-10-20	Eingeleitet	H.C. Wainwright	Buy
2016-10-07	Hochstufung	WBB Securities	Buy → Strong Buy
2016-10-03	Fortgesetzt	Brean Capital	Buy
2016-08-17	Eingeleitet	Guggenheim	Buy
2016-08-09	Bestätigt	Needham	Buy
2016-08-09	Hochstufung	WBB Securities	Speculative Buy → Buy
2016-03-28	Eingeleitet	Brean Capital	Buy
2015-12-29	Eingeleitet	WBB Securities	Speculative Buy
2015-11-16	Bestätigt	RBC Capital Mkts	Outperform
2015-06-10	Eingeleitet	Needham	Buy
2014-05-29	Eingeleitet	Canaccord Genuity	Buy
2014-05-29	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Scynexis Inc Aktie (SCYX) Neueste Nachrichten

Finanzdaten der Scynexis Inc-Aktie (SCYX)

Scynexis Inc (SCYX)

Scynexis Inc Stock (SCYX) Company Profile

Vergleichen Sie SCYX mit anderen Aktien

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Scynexis Inc Aktie (SCYX) Neueste Nachrichten

Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World

Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN

SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey

Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks

SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus

GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus

SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times

SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan

SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks

Biosergen taps antifungal expert as board member - Biostock

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News

SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World

SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Scynexis: Q1 Earnings Snapshot - CT Insider

SCYX Reports Strong Q1 Revenue, Progress in Clinical Trials | SCYX Stock News - GuruFocus

SCYX: Cash Reserves and Debt Repayment Update | SCYX Stock News - GuruFocus

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

SCYNEXIS INC SEC 10-Q Report - TradingView

Sector Update: Health Care Stocks Fall Late Afternoon - marketscreener.com

News - Biostock

SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday - Defense World

JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Sold by LPL Financial LLC - Defense World

Press Release Distribution & PR Platform - ACCESS Newswire

StockNews.com Begins Coverage on SCYNEXIS (NASDAQ:SCYX) - Defense World

GSK 'well positioned' for potential tariffs after beating forecasts - marketscreener.com

Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com

SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World

Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com

Second-Generation Antifungal Aims to Address Invasive Fungal Disease - ContagionLive

Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com

SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa

SCY-247 shows promise against resistant fungal infections - Investing.com

Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan

Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail

SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World

SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World

Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World

StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World

SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks

Finanzdaten der Scynexis Inc-Aktie (SCYX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SCYX